Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 134Cyclophosphamide 126Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 71Filgrastim 62Etoposide 56Bortezomib 44Vincristine 43Mycophenolic Acid 43Whole-Body Irradiation 42Cytarabine 42Cyclosporine 41Melphalan 38Doxorubicin 37Radiotherapy 36Busulfan 35ibrutinib 34Tacrolimus 34Methotrexate 33Prednisone 32Lenalidomide 30Bendamustine Hydrochloride 30Antilymphocyte Serum 27Dexamethasone 26Carmustine 26Granulocyte Colony-Stimulating Factor 23ibritumomab tiuxetan 20sargramostim 17fludarabine 17Methylprednisolone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Mantle-Cell × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡